Company Hikma Pharmaceuticals PLC

Equities

HIK

GB00B0LCW083

Pharmaceuticals

Market Closed - London S.E. 12:35:27 2024-03-28 pm EDT 5-day change 1st Jan Change
1,918 GBX +2.02% Intraday chart for Hikma Pharmaceuticals PLC -1.51% +7.24%

Business Summary

Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows:

- generic injectable products (45.3%);

- brand name drugs (27.5%);

- generic products taken orally (26.7%);

- other (0.5%).

Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).

Number of employees: 9,100

Sales per Business

GBP in Million2022Weight2023Weight Delta
Injectables
41.8 %
926 45.3 % 968 41.8 % +4.48%
Generics
32.6 %
546 26.7 % 754 32.6 % +38.17%
Branded
24.8 %
561 27.5 % 574 24.8 % +2.39%
Others
0.7 %
11 0.5 % 17 0.7 % +60.07%

Sales per region

GBP in Million2022Weight2023Weight Delta
United States
60.0 %
1,163 56.9 % 1,389 60.0 % +19.35%
Middle East and North Africa
12.7 %
308 15.1 % 294 12.7 % -4.31%
Saudi Arabia
9.1 %
195 9.5 % 210 9.1 % +7.76%
Europe and Rest of the World
7.2 %
170 8.3 % 166 7.2 % -2.79%
Algeria
6.6 %
107 5.2 % 152 6.6 % +41.88%
Egypt
3.2 %
93 4.6 % 75 3.2 % -19.86%
North America
0.8 %
-- 19 0.8 % -
United Kingdom
0.4 %
6 0.3 % 9 0.4 % +36.25%

Managers

Managers TitleAgeSince
Chief Executive Officer 60 89-12-31
Director of Finance/CFO 52 00-12-31
Chairman 66 80-12-31
Director/Board Member 65 84-12-31
Investor Relations Contact - 05-10-31
Sales & Marketing - 18-08-16
Corporate Officer/Principal - 21-12-31
Human Resources Officer - 00-12-31
Corporate Officer/Principal - 84-12-31
Corporate Officer/Principal 58 00-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 66 20-04-30
Director/Board Member 72 16-09-30
Director/Board Member 62 22-10-31
Director/Board Member 66 80-12-31
Director/Board Member 65 84-12-31
Director/Board Member 73 16-02-29
Chairman 66 80-12-31
Director/Board Member 64 19-05-31
Director/Board Member 63 14-03-31
Director/Board Member 59 22-10-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 234,718,492 153,733,558 ( 65.50 %) 12,833,233 ( 5.467 %) 65.50 %

Shareholders

NameEquities%Valuation
Darhold Ltd.
27.14 %
60,000,000 27.14 % 1 493 M p
Wellington Management Co. LLP
5.227 %
11,556,882 5.227 % 288 M p
Capital Research & Management Co. (World Investors)
3.459 %
7,646,798 3.459 % 190 M p
BlackRock Advisors (UK) Ltd.
2.780 %
6,146,057 2.780 % 153 M p
The Vanguard Group, Inc.
1.682 %
3,718,275 1.682 % 93 M p
Norges Bank Investment Management
1.628 %
3,599,000 1.628 % 90 M p
Royal London Asset Management Ltd.
1.110 %
2,454,000 1.110 % 61 M p
FIL Investment Advisors (UK) Ltd.
1.002 %
2,216,000 1.002 % 55 M p
Capital Research & Management Co. (Global Investors)
0.9828 %
2,172,839 0.9828 % 54 M p
BlackRock Fund Advisors
0.6568 %
1,452,000 0.6568 % 36 M p

Company contact information

Hikma Pharmaceuticals Plc

1 New Burlington Place

W1S 2HR, London

+44 20 7399 2760

http://www.hikma.com
address Hikma Pharmaceuticals PLC(HIK)

Group companies

NameCategory and Sector
Investment Managers
Hikma Finance USA LLC
Finance/Rental/Leasing

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
23.74 USD
Average target price
29.18 USD
Spread / Average Target
+22.89%
Consensus

Quarterly revenue - Rate of surprise